* Composition: Each 100 g contains:
Calcium dobesilate 4 g (=40mg/1g) + Lidocaine hydrochloride 2 g (=20mg/1g).
* Indications: (For the treatment of haemorrhoids)
Internal and external haemorrhoids. Anal pruritus. Anitis, perianitis, cryptitis, papillitis,
acute haemorrhoidal thrombosis, anal fissures.
Pre- and postoperative treatment in cases of haemorrhoidectomy.
* Dosage and administration:
– 2 – 3 applications daily.
– In the morning and at bedtime apply the ointment, if possible after defecation.
– In case of internal haemorrhoids, use the cannula by screwing it to the tube. Insert the cannula
as deep as possible in the anus then press gently the tube while withdrawing it. In this case,
the tube is sufficient for 10 applications.
– In case of external haemorrhoids or anal pruritus, apply a thin layer of the ointment several times a day.
– The duration of the treatment is generally of some days. The doctor must be informed if, after 1 to 2 weeks
of treatment, the symptomatology has not improved or has worsened.
– The treatment should not be repeated without previous medical advice.
* Limitations for use:
# Contraindications:
– Hypersensitivity towards the components of Doxiproct.
– Children under 14 years.
# Precautions:
– In case of renal insufficiency, the application of Doxiproct should be limited to a few days.
– In case of blood in the faeces or its suspected presence, as well as of a simultaneous occurrence
of pain and fever, the physician must be consulted.
– Treatment must be stopped in case of hypersensitivity reactions.
# Pregnancy and lactation:
– Pregnancy category C: Studies in pregnant women or animals are not available and in humans, it is not
known whether calcium dobesilate crosses the placental barrier. On the other hand, after topic administration,
lidocaine hydrochloride is resorbed in variable quantities and can have systemic effects. Moreover, it crosses
the placental barrier. In these conditions, Doxiproct® should be administered during pregnancy only if
the potential benefit justifies the potential risk to the fetus.
– After oral administration, calcium dobesilate is excreted into the maternal milk in low amounts, but it is not known
whether this is the case with local use. After topic administration, lidocaine hydrochloride is excreted into the
maternal milk. As a precaution, it should be decided between discontinuating the treatment or the breast-feeding.
* To be used only on medical advice.
* Store below 25 degrees C, protected from heat.
Related products
